Crescent Biopharma (C68) Stock Overview

A biotechnology company, researches and develops cancer therapy candidates in the United States. More details

C68 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 60.47% per year

Risk Analysis

Earnings are forecast to decline by an average of 12.5% per year for the next 3 years

Highly volatile share price over the past 3 months compared to the German market

Currently unprofitable and not forecast to become profitable over the next 3 years

C68 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Gain Therapeutics

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more

2.9k

US$7.6

72.1% undervalued

Lou_Basenese's

Fair Value

Profit Margin

18.91%

Future PE

25.12x

Price in 2031

US$10.68

Crescent Biopharma, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Crescent Biopharma
Historical stock prices
Current Share Price	US$17.40
52 Week High	US$17.70
52 Week Low	US$6.70
Beta	0
1 Month Change	107.14%
3 Month Change	61.11%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	42.93%

Recent updates

Shareholder Returns

	C68	DE Biotechs	DE Market
7D	18.4%	0.7%	2.7%
1Y	n/a	3.2%	10.2%

Return vs Industry: Insufficient data to determine how C68 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how C68 performed against the German Market.

Price Volatility

Is C68's price volatile compared to industry and market?
C68 volatility
C68 Average Weekly Movement	20.7%
Biotechs Industry Average Movement	9.1%
Market Average Movement	6.1%
10% most volatile stocks in DE Market	13.7%
10% least volatile stocks in DE Market	2.6%

Stable Share Price: C68's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: C68's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2024	44	Josh Brumm	crescentbiopharma.com

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Crescent Biopharma, Inc. Fundamentals Summary

How do Crescent Biopharma's earnings and revenue compare to its market cap?
C68 fundamental statistics
Market cap	€599.64m
Earnings (TTM)	-€130.60m
Revenue (TTM)	€9.20m

66.4x

P/S Ratio

-4.7x

P/E Ratio

Is C68 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
C68 income statement (TTM)
Revenue	US$10.84m
Cost of Revenue	US$0
Gross Profit	US$10.84m
Other Expenses	US$164.79m
Earnings	-US$153.94m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-4.63
Gross Margin	100.00%
Net Profit Margin	-1,419.61%
Debt/Equity Ratio	0%

How did C68 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/20 01:50
End of Day Share Price	2026/04/20 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Crescent Biopharma, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Eric Schmidt	Cantor Fitzgerald & Co.
Bradley Canino	Guggenheim Securities, LLC
Mitchell Kapoor	H.C. Wainwright & Co.

Crescent Biopharma, Inc.DB:C68 Stock Report